Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending August 2014. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility (PDMRs), and Connected Persons in accordance with DTR 3.1.4R(1)(a) and (c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is limited to reporting specific share acquisition activities under the GSK ShareReward Plan.
On August 11, 2014, the following transactions occurred at a price of 1378.19 pence per Ordinary Share:
- Directors/PDMRs: Acquired shares through personal contributions and matching GSK contributions. Most directors acquired 9 shares in each element, while Dr. P J T Vallance acquired 10 shares in each element, and Mr. P C Thomson acquired 8 shares in each element.
- Connected Person: Mrs. K Thomson (connected to Mr. P C Thomson) acquired 2 shares under the personal contribution element and 2 shares under the matching element.
Material Changes
The filing text does not provide a clear value for material changes in financial performance versus the prior comparable period. The document focuses solely on the disclosure of recent insider share acquisitions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. No strategic updates or risk disclosures are included in this specific notification.
Investor Verification Checklist
- Verify the total number of shares acquired by directors and connected persons under the ShareReward Plan.
- Confirm the transaction price of 1378.19 pence per share against market data for August 11, 2014.
- Review the full list of participating Directors and PDMRs to ensure compliance with internal governance policies.
- Check subsequent filings for broader financial performance data, as this 6-K is limited to transaction notifications.